The prognostic model was developed using datasets that included both IDH-mutant and IDH–wild-type gliomas; although it showed strong performance overall, further validation in IDH–wild-type glioblastomas, which represent a distinct and aggressive subgroup, is needed. Here, IDH1 is linked to glioblastoma.